The At its meeting in December 2022 a Extension forDapagliflozin (Forxiga, Edistride, AstraZeneca) recommended:
The SGLT-2 inhibitor is indicated in adults for the treatment of symptomatic chronic heart failure, with the restriction to patients with «reduced ejection fraction» to be eliminated in the future.
Dapagliflozin is also used in type 2 diabetes mellitus and chronic kidney disease.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassungserweiterung-f%25C3%25BCr-dapagliflozin-2022a10028od
Comments are closed.